Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,308.00GBp
17 Nov 2017
Change (% chg)

-- (--)
Prev Close
1,308.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,288,442
52-wk High
1,724.50
52-wk Low
1,300.00

Select another date:

Thu, Nov 16 2017

BRIEF-‍GlaxoSmithKline reports 13.3 percent stake in Spero Therapeutics

* ‍GlaxoSmithKline PLC reports a 13.3 percent stake in Spero Therapeutics Inc as of November 6 - SEC filing​ Source text: (http://bit.ly/2infUEI) Further company coverage:

Europe approves GlaxoSmithKline's new triple lung drug

LONDON Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair.

Europe approves GlaxoSmithKline's new triple lung drug

LONDON, Nov 16 Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair.

BRIEF-GlaxoSmithKline says European Commission grants marketing authorisation for Trelegy Ellipta

* TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY GAINS MARKETING AUTHORISATION IN EUROPE FOR TREATMENT OF COPD​ Source text for Eikon: Further company coverage:

BRIEF-Glaxosmithkline posts Q1 consol profit

* Q1 CONSOL NET PROFIT EGP 18.2 ‍​MILLION VERSUS LOSS OF EGP 72.9 ‍​MILLION YEAR AGO

BRIEF-GlaxoSmithkline receives European marketing authorisation for self-injectable formulation of Benlysta for treatment of systemic lupus erythematosus

* RECEIVES EUROPEAN MARKETING AUTHORISATION FOR SELF-INJECTABLE FORMULATION OF BENLYSTA FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS​

AstraZeneca rides China wave as rival GlaxoSmithKline struggles

LONDON AstraZeneca is enjoying booming drug sales in China, helped by reforms to the country's regulatory system and an increased sales force, in sharp contrast to its British rival GlaxoSmithKline .

AstraZeneca rides China wave as rival GlaxoSmithKline struggles

LONDON, Nov 9 AstraZeneca is enjoying booming drug sales in China, helped by reforms to the country's regulatory system and an increased sales force, in sharp contrast to its British rival GlaxoSmithKline.

BRIEF-Glaxosmithkline says ‍Hal Barron appointed as chief scientific officer and president, research and development​

* ‍HAL BARRON HAS BEEN APPOINTED CHIEF SCIENTIFIC OFFICER AND PRESIDENT, RESEARCH AND DEVELOPMENT​

Fitch Affirms GSK at 'A'; Stable Outlook

(The following statement was released by the rating agency) LONDON, November 01 (Fitch) Fitch Ratings has affirmed UK-based pharmaceuticals company GlaxoSmithKline PLC's (GSK) Long-Term Issuer Default Rating (IDR) at 'A' with Stable Outlook. Fitch has also affirmed the senior unsecured rating at 'A' for the debt issued by GlaxoSmithKline PLC, GlaxoSmithKline Capital PLC, and GlaxoSmithKline Capital Inc. The affirmation reflects Fitch's expectation that GSK's leverage should remain at the top end

Select another date: